Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Real Time Quote from BATS)

$111.41 USD

111.41
354,247

+1.95 (1.78%)

Updated Apr 29, 2024 01:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session

by Zacks Equity Research

Enanta Pharmaceuticals, Inc. (ENTA) was a big mover last session, as the company saw its shares rise over 9% on the day.

    Ironwood Pharma's Combination Gout Drug Gets FDA Approval

    by Zacks Equity Research

    Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.

      Swarup Gupta headshot

      Rally Set to Resume: Buy These 5 Value Picks on the Dip

      by Swarup Gupta

      Morgan Stanley believes that conditions for a Bull Run remain in place.

        Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer

        by Zacks Equity Research

        Jazz Pharmaceuticals (JAZZ) announces private offering of exchangeable senior notes to qualified institutional buyers to raise proceeds and repay debt.

          Endo International (ENDP) Jumps: Stock Rises 6.9%

          by Zacks Equity Research

          Endo International (ENDP) was a big mover last session, as the company saw its shares rise almost 7% on the day amid huge volumes.

            Jounce Therapeutics (JNCE) Jumps: Stock Moves 7.4% Higher

            by Zacks Equity Research

            Jounce Therapeutics, Inc. (JNCE) moved big last session, as its shares jumped over 7% on the day.

              Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact

              by Zacks Equity Research

              Jazz Pharma's (JAZZ) earnings and revenues miss estimates. However, the top line rises year over year owing to higher sales of the company's marketed drug, Xyrem.

                Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?

                by Zacks Equity Research

                Jazz Pharma's (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q2, thanks to label expansion efforts.

                  AVEO's Kidney Cancer Candidate Gets CHMP Recommendation

                  by Zacks Equity Research

                  AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).

                    Why Is Jazz Pharmaceuticals (JAZZ) Down 3.3% Since the Last Earnings Report?

                    by Zacks Equity Research

                    Jazz Pharmaceuticals (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Jazz Pharma Sleep Disorder Candidate Positive in Phase III

                      by Zacks Equity Research

                      Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy results from studies evaluating its lead pipeline candidate, JZP-110, in adult patients with excessive sleepiness (ES) associated with narcolepsy and obstructive sleep apnea (OSA).

                        Jazz Pharmaceuticals' Vyxeos NDA Granted Priority Review

                        by Zacks Equity Research

                        Jazz Pharmaceuticals plc (JAZZ) announced that the New Drug Application (NDA) for its experimental leukemia candidate Vyxeos has been accepted for priority review by the FDA.

                          BioLineRx Makes Regulatory Submission for Trial of BL-8040

                          by Zacks Equity Research

                          BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).

                            Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales

                            by Zacks Equity Research

                            Jazz Pharmaceuticals Public Limited Company (JAZZ) reported first-quarter 2017 earnings of $1.41 per share, which narrowly missed the Zacks Consensus Estimate of $1.42.

                              Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?

                              by Zacks Equity Research

                              Jazz Pharmaceuticals plc (JAZZ) is scheduled to report first-quarter 2017 results on May 9, after the market closes.

                                Jazz Pharma Completes NDA Filing for Leukemia Drug to FDA

                                by Zacks Equity Research

                                Jazz Pharmaceuticals plc (JAZZ) recently announced that it has completed the rolling submission of a new drug application (NDA) to the FDA, seeking approval for its leukemia candidate, Vyxeos.

                                  Jazz Pharma (JAZZ) Up 7.6% Since Earnings Report: Can It Continue?

                                  by Zacks Equity Research

                                  Jazz Pharma (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                    Jazz Sleep Disorder Drug Positive in Phase III Studies

                                    by Zacks Equity Research

                                    Jazz Pharmaceuticals plc (JAZZ) recently announced positive efficacy results from two phase III studies evaluating the safety and efficacy of its lead pipeline candidate JZP-110 for the treatment of excessive sleepiness.

                                      Jazz Initiates Phase III Study for Narcolepsy Candidate

                                      by Zacks Equity Research

                                      Jazz Pharmaceuticals plc (JAZZ) recently announced the initiation of patient enrollment in a phase III study evaluating the efficacy and safety of its pipeline candidate, JZP-258, for the potential treatment of adult narcolepsy patients.

                                        Jazz Pharma (JAZZ) Q4 Earnings Beat, Sales Miss Estimates

                                        by Zacks Equity Research

                                        Jazz Pharmaceuticals Public Limited Company (JAZZ) reported fourth-quarter 2016 earnings of $1.91 per share which beat the Zacks Consensus Estimate of $1.65.

                                          Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?

                                          by Zacks Equity Research

                                          Jazz Pharmaceuticals plc (JAZZ) is scheduled to report fourth-quarter 2016 results on Feb 28 after the market closes.

                                            Arpita Dutt headshot

                                            5 Drug Stocks Poised to Beat Earnings Estimates in Q4

                                            by Arpita Dutt

                                            Medical is one of the few sectors that has consistently recorded earnings growth over the last 4 quarters. Here is a look at 5 pharma and biotech stocks that look set to beat Q4 earnings estimates.

                                              Can Jazz Pharmaceuticals Be a Top Choice for Value Investors?

                                              by Zacks Equity Research

                                              Value investing is easily one of the most popular ways to find great stocks in any market environment.

                                                Can Jazz Pharmaceuticals Be a Top Choice for Value Investors?

                                                by Zacks Equity Research

                                                Let's see if Jazz Pharmaceuticals Public Limited Company (JAZZ) stock is a good choice for value-oriented investors right now from multiple angles.

                                                  Jazz Begins Phase III Study for Label Expansion of Defitelio

                                                  by Zacks Equity Research

                                                  Jazz Pharmaceuticals Public Limited Company (JAZZ) announced the initiation of a phase III clinical study on its marketed drug, Defitelio (defibrotide), for the potential prevention of veno-occlusive disease.